256 related articles for article (PubMed ID: 9418856)
1. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
Barrington RE; Subler MA; Rands E; Omer CA; Miller PJ; Hundley JE; Koester SK; Troyer DA; Bearss DJ; Conner MW; Gibbs JB; Hamilton K; Koblan KS; Mosser SD; O'Neill TJ; Schaber MD; Senderak ET; Windle JJ; Oliff A; Kohl NE
Mol Cell Biol; 1998 Jan; 18(1):85-92. PubMed ID: 9418856
[TBL] [Abstract][Full Text] [Related]
2. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.
Bearss DJ; Subler MA; Hundley JE; Troyer DA; Salinas RA; Windle JJ
Oncogene; 2000 Feb; 19(8):1114-22. PubMed ID: 10713698
[TBL] [Abstract][Full Text] [Related]
3. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.
Kohl NE; Omer CA; Conner MW; Anthony NJ; Davide JP; deSolms SJ; Giuliani EA; Gomez RP; Graham SL; Hamilton K
Nat Med; 1995 Aug; 1(8):792-7. PubMed ID: 7585182
[TBL] [Abstract][Full Text] [Related]
5. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
Nørgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ; Poulsen HS; Moses HL
Clin Cancer Res; 1999 Jan; 5(1):35-42. PubMed ID: 9918200
[TBL] [Abstract][Full Text] [Related]
6. p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors.
Petit T; Bearss DJ; Troyer DA; Munoz RM; Windle JJ
Mol Cancer Ther; 2003 Feb; 2(2):165-71. PubMed ID: 12589033
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors.
Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Barrington RE; Windle JJ
Cancer Res; 1997 Feb; 57(4):600-3. PubMed ID: 9044833
[TBL] [Abstract][Full Text] [Related]
10. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53.
Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Subler MA; Windle JJ
Mol Cell Biol; 1997 Feb; 17(2):723-31. PubMed ID: 9001226
[TBL] [Abstract][Full Text] [Related]
11. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
13. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
[TBL] [Abstract][Full Text] [Related]
14. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor.
Russo P; Arzani D; Trombino S; Falugi C
J Pharmacol Exp Ther; 2003 Jan; 304(1):37-47. PubMed ID: 12490573
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.
Sinn E; Muller W; Pattengale P; Tepler I; Wallace R; Leder P
Cell; 1987 May; 49(4):465-75. PubMed ID: 3032456
[TBL] [Abstract][Full Text] [Related]
17. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
Sepp-Lorenzino L; Rosen N
J Biol Chem; 1998 Aug; 273(32):20243-51. PubMed ID: 9685373
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets.
Yao R; Wang Y; Lu Y; Lemon WJ; End DW; Grubbs CJ; Lubet RA; You M
Carcinogenesis; 2006 Jul; 27(7):1420-31. PubMed ID: 16403772
[TBL] [Abstract][Full Text] [Related]
19. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Balasis ME; Forinash KD; Chen YA; Fulp WJ; Coppola D; Hamilton AD; Cheng JQ; Sebti SM
Clin Cancer Res; 2011 May; 17(9):2852-62. PubMed ID: 21536547
[TBL] [Abstract][Full Text] [Related]
20. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
Cohen-Jonathan E; Evans SM; Koch CJ; Muschel RJ; McKenna WG; Wu J; Bernhard EJ
Cancer Res; 2001 Mar; 61(5):2289-93. PubMed ID: 11280800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
